Cargando…

Imatinib mesylate resistance and mutations: An Indian experience

The treatment of chronic myeloid leukemia (CML) has been revolutionized by the small molecule selective kinase inhibitor imatinib mesylate. Imanitib was the first BCR-ABL targeted agent approved for the treatment of CML patients and confers significant response in most patients; however, a substanti...

Descripción completa

Detalles Bibliográficos
Autores principales: Srivastava, Shweta, Dutt, Sarjana
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Medknow Publications & Media Pvt Ltd 2013
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3902630/
https://www.ncbi.nlm.nih.gov/pubmed/24516315
http://dx.doi.org/10.4103/0971-5851.123748
_version_ 1782301017717604352
author Srivastava, Shweta
Dutt, Sarjana
author_facet Srivastava, Shweta
Dutt, Sarjana
author_sort Srivastava, Shweta
collection PubMed
description The treatment of chronic myeloid leukemia (CML) has been revolutionized by the small molecule selective kinase inhibitor imatinib mesylate. Imanitib was the first BCR-ABL targeted agent approved for the treatment of CML patients and confers significant response in most patients; however, a substantial number of patients are initially refractory to the drug or may develop resistance during the course of treatment. Point mutations in the kinase domain (KD) of BCR-ABL that impact drug binding have been identified as one of the major mechanisms of resistance. We present here an overview of the current practice in monitoring for such mutations, including the methods used, criteria for investigating and guidelines for reporting the mutations. We further present and discuss the experience of our own laboratory in studying the KD mutations in Indian CML patients on imatinib treatment.
format Online
Article
Text
id pubmed-3902630
institution National Center for Biotechnology Information
language English
publishDate 2013
publisher Medknow Publications & Media Pvt Ltd
record_format MEDLINE/PubMed
spelling pubmed-39026302014-02-10 Imatinib mesylate resistance and mutations: An Indian experience Srivastava, Shweta Dutt, Sarjana Indian J Med Paediatr Oncol Original Article The treatment of chronic myeloid leukemia (CML) has been revolutionized by the small molecule selective kinase inhibitor imatinib mesylate. Imanitib was the first BCR-ABL targeted agent approved for the treatment of CML patients and confers significant response in most patients; however, a substantial number of patients are initially refractory to the drug or may develop resistance during the course of treatment. Point mutations in the kinase domain (KD) of BCR-ABL that impact drug binding have been identified as one of the major mechanisms of resistance. We present here an overview of the current practice in monitoring for such mutations, including the methods used, criteria for investigating and guidelines for reporting the mutations. We further present and discuss the experience of our own laboratory in studying the KD mutations in Indian CML patients on imatinib treatment. Medknow Publications & Media Pvt Ltd 2013 /pmc/articles/PMC3902630/ /pubmed/24516315 http://dx.doi.org/10.4103/0971-5851.123748 Text en Copyright: © Indian Journal of Medical and Paediatric Oncology http://creativecommons.org/licenses/by-nc-sa/3.0 This is an open-access article distributed under the terms of the Creative Commons Attribution-Noncommercial-Share Alike 3.0 Unported, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
spellingShingle Original Article
Srivastava, Shweta
Dutt, Sarjana
Imatinib mesylate resistance and mutations: An Indian experience
title Imatinib mesylate resistance and mutations: An Indian experience
title_full Imatinib mesylate resistance and mutations: An Indian experience
title_fullStr Imatinib mesylate resistance and mutations: An Indian experience
title_full_unstemmed Imatinib mesylate resistance and mutations: An Indian experience
title_short Imatinib mesylate resistance and mutations: An Indian experience
title_sort imatinib mesylate resistance and mutations: an indian experience
topic Original Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3902630/
https://www.ncbi.nlm.nih.gov/pubmed/24516315
http://dx.doi.org/10.4103/0971-5851.123748
work_keys_str_mv AT srivastavashweta imatinibmesylateresistanceandmutationsanindianexperience
AT duttsarjana imatinibmesylateresistanceandmutationsanindianexperience